title: Intravenous nifedipine to treat hypertension after coronary artery revascularization surgery. A comparison with sodium nitroprusside.
abstract: We administered sodium nitroprusside (SNP) or nifedipine intravenously to patients who became hypertensive after elective coronary revascularization and compared their effects on hemodynamics and the electrocardiogram in a parallel, randomized, open-label study. Four of 21 patients treated with nifedipine required the addition of SNP to maintain mean arterial pressure less than 90 mm Hg, compared with 4 of 28 patients in the SNP group who required the addition of nifedipine. The success rates of nifedipine (81%) and SNP (86%) were not significantly different. There was no difference in the incidence of adverse ST-segment changes during drug infusion (4% versus 5%) or perioperative myocardial infarction (9.5% versus 10.7%) in the nifedipine versus SNP groups, respectively. The plasma nifedipine concentration (mean value +/- SD) at steady state for 21 patients receiving nifedipine was 119 +/- 42.5 ng/mL. The pharmacokinetic variables for nifedipine were as follows (mean values +/- SD): systemic clearance, 0.525 +/- 0.228 L.h-1.kg-1; apparent volume of distribution, 0.738 +/- 0.446 L/kg; and elimination half-life, 1.02 +/- 0.51 h. These values are similar to those reported previously in healthy volunteers. We conclude that intravenous nifedipine can be used safely to control hypertension after coronary revascularization but were unable to demonstrate an advantage of nifedipine compared with SNP in preventing postoperative ischemia or infarction in this group of patients who had good left ventricular function.
authors.affiliation: Department of Anesthesia, University of Ottawa, Ontario, Canada.
authors.forename: H J
authors.initials: HJ
authors.lastname: Nathan
authors.forename: S
authors.initials: S
authors.lastname: Laganière
authors.forename: L
authors.initials: L
authors.lastname: Dubé
authors.forename: B
authors.initials: B
authors.lastname: Foster
authors.forename: I
authors.initials: I
authors.lastname: McGilveray
authors.forename: M
authors.initials: M
authors.lastname: Harrison
authors.forename: M
authors.initials: M
authors.lastname: Bourke
authors.forename: C
authors.initials: C
authors.lastname: Cattran
authors.forename: G
authors.initials: G
authors.lastname: de LaSalle
authors.forename: J
authors.initials: J
authors.lastname: Robblee
mesh_terms: D001794:Blood Pressure / Q000187:drug effects; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D003327:Coronary Disease / Q000517:prevention & control; D003402:Creatine Kinase / Q000032:analysis; D015716:Electrocardiography, Ambulatory; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology; D007262:Infusions, Intravenous; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control; D009204:Myocardial Revascularization / Q000009:adverse effects*; D009543:Nifedipine / Q000008:administration & dosage / Q000627:therapeutic use*; D009599:Nitroprusside / Q000627:therapeutic use*
chemical_list: D007527:Isoenzymes; D009599:Nitroprusside; D003402:Creatine Kinase; D009543:Nifedipine